@CoulterPartners - May 18 Michael Huberts hopes to see you at AusMedtech 2022 at the Melbourne Convention Centre, Australia, next week, 24-26… https://t.co/6OSYa1iO7K
@CoulterPartners - May 18 Penny Sadler is looking forward to the annual Knowledge for Growth conference this week at the International Conven… https://t.co/zw1cqnc8V2
@CoulterPartners - May 17 Our team are enjoying Bio€quity Europe in Milan, where today's Next Generation Leadership panel was a particular hi… https://t.co/DPjLha9kr5
@CoulterPartners - May 17 Coulter Partners is pleased to announce the placement of J.D. Mowery as Chief Operating Officer (COO) at Treadwell… https://t.co/szPBm7oWrv
@CoulterPartners - May 16 We hope to see you in Milan at Bio€quity Europe this week! We are particularly excited for the session on Next Gene… https://t.co/4VoJifUDX5
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.AcceptRead More
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
Coulter Partners recently partnered with Treadwell Therapeutics, a clinical-stage biotechnology company developing novel, cross-modality medicines for unmet needs in cancer, and is pleased to announce the placement of J.D. Mowery as Chief Operating Officer (COO).
Coulter Partners announces two additional appointments to its new Milan office. Giulia Bacis joins as Senior Consultant and Anna Senzacqua as Consultant. Together with Francesca Lazzarin, Executive Director, Yasemin Holland, Senior Research Associate and Giuliana Milioto, Research Associate, they make up the Italian team who will enrich the firm’s offering to companies growing from Italian headquarters and those expanding into Italy.
Coulter Partners announces the opening of its new office in Milan and two additional key appointments. Francesca Lazzarin joins as Executive Director and Giuliana Milioto as Research Associate. We will be announcing two further appointments next week. They will all work across Europe with a particular focus on the Italian market, alongside recently appointed Yasemin Holland, Senior Research Associate. These new colleagues will particularly enrich the firm’s offering to companies growing from Italian headquarters and those expanding into Italy.
Executive Director Michael Huberts shares his insights on senior leadership hiring in the Australian Life Sciences, Health, and Tech sectors.
He explores the impact of the global Covid pandemic, the challenges of shrinking talent pools, government initiatives and investments, leadership diversity, digital health, and current trends.
A selection of recent successful placements and new projects globally. Focus in the first quarter of 2022 has been predominantly: Precision medicine, Radiopharmaceuticals, Immuno-oncology, Drug discovery services, Women’s health, A.I. for drug discovery, Veterinary services, Regenerative medicine, Age-related diseases, Rare diseases, Nutraceuticals and Genomics
“I like the excitement of not knowing what’s going to happen and I think I thrive on it.”
For the first interview in our Human Strategy Series, the team recently spoke with Dr Jackie Ameri, CEO of Pancryos, who benefited from our Leadership Assessment service as part of the partnership between Coulter Partners and the BioInnovation Institute (BII). Jackie discusses her early career, her decision to join the BII and highlights the benefits of being part of the BII Creation House Program.
Coulter Partners recently partnered with Totus Medicines, the drug discovery company using breakthrough chemical biology to make the entire human genome druggable, and was pleased to secure the appointment of Dr. Wei Chen and Daisy Chhokar as the company’s first Chief Scientific Officer (CSO) and Chief People Officer (CPO), respectively.
As we celebrate International Women’s Day and continue to push on breaking biases, our CEO and Co-founder Bianca Coulter shares a few of her own perception.
“…I believe that specifically in healthcare, diversity is hugely important. The most critical value of diversity in healthcare is to improve patient outcomes…”
As part of our Diversity, Equity & Inclusion Leadership series, we spoke to Corinne Le Goff, until recently Chief Commercial Officer at Moderna, a pioneer in mRNA therapeutics and developer of the second mRNA COVID-19 vaccine to be approved. Corinne brings over 30 years’ experience in pharmaceuticals, having held senior strategic and commercial leadership roles at Amgen, Roche, Merck AG and Sanofi, mostly in the US, but also in France and Switzerland.
Coulter Partners, the global experts in Executive Search and Leadership Development in Life Sciences, Health and Tech, has appointed four young professionals in the US and nine at its London headquarters in the last 12 months, concluding an extremely successful 2021 and looking forward to a very exciting 2022.
A selection of recent successful placements and new projects globally. Focus in the last quarter of 2021 has been predominantly: Digital Diagnostics, CNS/ Neuro, Microbiome, Research Services, Veterinary Services, Dental Services, DNA/ RNA, Surgical Robotics, Synthetic Biology, Gene therapy, Oncology and Digital Therapeutics.
“…we should bear in mind that “minoritized ethnic and racial groups” are not homogenous but people with very diverse cultural backgrounds within them and with very different histories of success within a country …”
For the fifth instalment of our Diversity, Equity & Inclusion Leadership series, the team recently had an insightful conversation with Dr. Dipti Amin, Director at Maaya Associates Ltd and a Non-Executive Director at Lineage Cell Therapeutics, Buckinghamshire Healthcare NHS Trust, and the University of Hertfordshire. Previously, Chief Compliance Officer at Quintiles Transnational (now IQVIA) Dr Amin brings 29 years’ experience in positions of operational and strategic responsibility within Pharmaceutical Services at the C-suite and Board level.
Coulter Partners partnered recently with Apollo Therapeutics, a portfolio-based biopharmaceutical company rapidly advancing transformative treatments based on breakthrough discoveries, and was pleased to secure the appointment of Dr. Sanjay Aggarwal as the company’s Chief Medical Officer.
Our CEO Bianca Coulter interviews John Dawson, CEO of Oxford Biomedica, who shares up-to-the-minute insights on leadership and innovation in unprecedented times.
Watch the recording in case you missed it.
“Culturally, we have been educated to assume that top leaders must know the best and the most, but inclusion is the opposite, it is making sure that we learn from others.”
For the fourth instalment of our Diversity, Equity & Inclusion Leadership series, the team recently explored D, E & I perspectives from the medtech industry with Guillaume Julien, VP HR Global Sales at Getinge, a leading global provider of medical products and systems, employing more than 10,000 people, with operations in 38 countries.
Coulter Partners was pleased to partner recently with Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, to secure the appointments of three new members to its Board of Directors.
A selection of C-suite, board, strategic commercial, R&D, medical and technical executive appointments for the past six months. Global hiring continues strongly and we look forward to collaborating on future projects!
Coulter Partners was pleased to partner recently with Enthera Pharmaceuticals (“Enthera”), a biotech company developing first-in-class biologics for selected autoimmune conditions based on the discovery of a novel apoptosis pathway, to secure the appointment of Antonio Speziale as Chief Medical Officer.
Coulter Partners was pleased to partner recently with MiNA Therapeutics Limited (“MiNA” or the “Company”), the pioneer in small activating RNA (saRNA) therapeutics, to secure the appointments of Troels Koch, Senior Vice President, Chemistry and Ilian Tchakov, Vice President, Clinical Development.
A selection of recent successful placements and new projects globally. Focus in the 3rd quarter of 2021 has been predominantly: Immunology, Oncology, Rare Diseases, Infectious diseases, Neuro-degeneration, A.I. for drug discovery, DNA/ RNA, Vaccines, Drug delivery, Wound care, Telehealth, and Veterinary Services.
Coulter Partners announces the appointment of Dr Christelle Kerouedan as Marketing Director.
Christelle’s career has been dedicated to the Life Sciences and Technology sectors with experience gained in academia, start-ups, and communications agencies over the last 24 years. She combines strong marketing & communications expertise with hands-on entrepreneurial management experience, leadership and coaching skills, and a deeply rooted science understanding.
Coulter Partners was delighted to partner with Civetta Therapeutics, LLC, a biotechnology company focused on developing a pipeline of therapies that target beta-propeller proteins, to secure the appointment of Christopher D. Roberts, Ph.D., as Chief Executive Officer.
Dr. Roberts, who most recently served as Chief Scientific Officer of Black Diamond Therapeutics, brings more than 20 years of leadership experience discovering and developing novel therapies for oncology, immunology, virology and other indications.
“Good practice means that you have a diverse inclusive board and C-suite, not just token but systematic, and it needs to be beyond just gender and ethnicity. It's the different ways of thinking that matter.”
For the third instalment of our D&I Leadership series, the team recently had the privilege to spend some time with Dame Kate Bingham, Managing Partner at venture capital firm SV Health Investors, and former Chair of the Government's Vaccine Taskforce.
A selection of recent successful placements and new projects globally. Focus in the 2nd quarter of 2021 has been predominantly Gene Therapy, Oncology, Synthetic Biology, Cardiovascular, CNS Diseases, Respiratory Diseases, Animal Health, Drug Delivery, Rare Diseases, Digital Therapeutics, P.O.C. Diagnostics and Implantable Technologies.
Coulter Partners was very pleased to partner recently with Memo Therapeutics AG, an innovator in the field of antibody discovery and development, to secure the appointment of Dr. George Badita as Chief Medical Officer. “George brings his extensive expertise in Translational Medicine and Clinical Drug Development as the company is in a pivotal stage of growth and prepares to transition to a clinical-stage organization. I thank the Coulter Partners team for their outstanding professional support in securing George’s appointment,” commented CEO, Dr. Karsten Fischer.
The June HR Leadership Forum was focused on the topic of Diversity, Equity and Inclusion. Discussion revolved around these topics: 1) The Business Case – where are your organisations on the business case for D, E & I? How well is this understood by your organisation and do you see the link between diverse teams and better business performance?
2) The Inputs – what are you doing to improve diversity in the organisation? How do you select interventions that will work?
3) The Outputs – linked to the business case, what results, both tangible and intangible, are you seeing in the business because of a more diverse team?
Find out more...
Coulter Partners was very pleased to partner recently with 2N Pharma, a biotech company developing therapeutic drugs to treat neurological disorders, to secure the appointments of Alex Leech as Chair of the Board of Directors and John Kemp as Non-Executive Director. Coulter Partners and BioInnovation Institute have a Partnership Agreement to support BII Creation House companies as they build and develop their Boards and Executive teams.
“The business proof is in the outcome and the metrics should convince any doubters that diversity always wins”
For the second in this series of interviews, Coulter Partners recently talked about the importance of diversity, equity and inclusion in Life Sciences with Dr. Jason Mellad, CEO and Co-Founder of Start Codon, a Cambridge based accelerator. Dr. Mellad was previously CEO of Cambridge Epigenetix, a company pioneering the development and application of novel epigenetics-based diagnostics and therapeutics.
Coulter Partners recently partnered with the European Sperm Bank to bring more digital experience to their board. Fertility, life choices and women’s health are areas where Coulter Partners is now seeing a great deal more interest and investment. The CP team caught up with Jesper Funding Andersen – Chair of European Sperm Bank - to discuss this broad topic...
"To be innovative, competitive and disruptive, we need to be inclusive." In the first in a series of interviews with industry leaders about the importance of diversity, equity and inclusion in Life Sciences, Coulter Partners talks to Annalisa Jenkins, MBBS, FRCP. Dr. Jenkins serves as Chair and Independent Director on the boards of several Biopharma organisations and was previously President and CEO of Dimension Therapeutics.
Coulter Partners was delighted to partner again with Azitra Inc., to secure the appointment of Francisco Salva as President and Chief Executive Officer. Mr. Salva most recently served as President and Chief Executive Officer of Complexa, a clinical stage company developing innovative therapies for fibrotic and inflammatory diseases. Azitra is the first synthetic biology company focused on discovering and developing therapies to address serious skin conditions by harnessing the microbiome.